CEO is brewing a "big move" acquisition, aiming to increase the market value of GameStop Corp. Class A (GME.US) to over $100 billion.
As of press time, the stock has risen more than 3.7%, reaching $23.66.
Ryan Cohen, CEO of American game retailer GameStop Corp. Class A (GME.US), stated that the company is considering a major acquisition, with the target possibly being a publicly traded company in the consumer or retail sector.
In an interview published on Thursday, Conn's, Inc. said that the consumer and retail industries have always been an important focus of his career, and he hopes to build GameStop Corp. Class A, currently valued at around $11 billion, into a "giant company with a market value of over $100 billion." He emphasized that the future deal size will be "very big," and admitted that this decision will be either "genius or an utter folly."
He revealed that they are evaluating a few companies, but did not disclose specific names, and plan to actively engage potential acquisition targets in the near future. Financially, GameStop Corp. Class A has around $9 billion in cash and liquid securities on its balance sheet, providing ample financial support for potential mergers.
Conn's, Inc.'s statement has also drawn market attention. Prominent investor Michael Burry, a shareholder of GameStop Corp. Class A, publicly praised Conn's, Inc. for maintaining restraint in capital allocation and believes that potential acquisitions will be an important driver in enhancing shareholder value. As of the time of writing, the stock has risen by over 3.7%, closing at $23.66.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


